Agonistic anti-CD137 antibody treatment leads to antitumor response in mice with liver cancer

International Journal of Cancer

Volumn 135, Issue 12, 2014, Pages 2857-2867

  Gauttier, Vanessa ^a   Judor, Jean Paul ^a   Guen, Valentin Le ^a   Cany, Jeannette ^b   Ferry, Nicolas ^b   Conchon, Sophie ^a  

^a INSERM   (France)

^b Centre National de la Recherche Scientifique   (France)

Author keywords

4 1BB; Combination immunotherapy; Hepatocellular carcinoma; Liver cancer; MDSC; Therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CD137 ANTIGEN; MONOCLONAL ANTIBODY;

ADOPTIVE TRANSFER; AGONISTS; ANIMAL; C3H MOUSE; C57BL MOUSE; CANCER TRANSPLANTATION; CARCINOMA, HEPATOCELLULAR; CD8+ T LYMPHOCYTE; CYTOLOGY; IMMUNOLOGY; IMMUNOTHERAPY; LIVER NEOPLASMS; MACROPHAGE; MALE; METABOLISM; MOUSE; NATURAL KILLER CELL; PROCEDURES; REGULATORY T LYMPHOCYTE;

ADOPTIVE TRANSFER; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD137; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CD8-POSITIVE T-LYMPHOCYTES; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LIVER NEOPLASMS; MACROPHAGES; MALE; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; T-LYMPHOCYTES, REGULATORY;

EID: 84908691666     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28943     Document Type: Article

References (40)

1. Schutte K, Bornschein J, Malfertheiner P. Hepatocellular carcinoma-epidemiological trends and risk factors. Dig Dis 2009;27:80-92.
2. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008;48 (Suppl 1):S20-37.
3. Stauffer JK, Scarzello AJ, Jiang Q, et al. Chronic inflammation, #immune |escape, and oncogenesis in the liver: a unique neighborhood for novel intersections. Hepatology 2012;56:1567-74.
4. Gao Q, Qiu SJ, Fan J, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 2007;25:2586-93.
5. Mizukoshi E, Nakamoto Y, Arai K, et al. Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma. Hepatology 2011;53:1206-16.
6. Zerbini A, Pilli M, Soliani P, et al. Ex vivo characterization of tumor-derived melanoma antigen encoding gene-specific CD81 cells in patients with hepatocellular carcinoma. J Hepatol 2004;40:102-9.
7. Sawada Y, Yoshikawa T, Nobuoka D, et al. Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival. Clin Cancer Res 2012;18:3686-96.
8. Tada F, Abe M, Hirooka M, et al. Phase I/II study of immunotherapy using tumor antigenpulsed dendritic cells in patients with hepatocellular carcinoma. Int J Oncol 2012;41:1601-9.
9. Takayama T, Sekine T, Makuuchi M, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000;356:802-7.
10. Melero I, Murillo O, Dubrot J, et al. Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies. Trends Pharmacol Sci 2008;29:383-90.
11. Hurtado JC, Kim SH, Pollok KE, et al. Potential role of 4-1BB in T cell activation. Comparison with the costimulatory molecule CD28. J Immunol 1995;155:3360-7.
12. Hurtado JC, Kim YJ, Kwon BS. Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell death. J Immunol 1997;158:2600-9.
13. Shuford WW, Klussman K, Tritchler DD, et al. 4-1BB costimulatory signals preferentially induce CD8 1 T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med 1997;186:47-55.
14. Melero I, Shuford WW, Newby SA, et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 1997;3:682-5.
15. Kim JA, Averbook BJ, Chambers K, et al. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation. Cancer Res 2001;61:2031-7.
16. Houot R, Goldstein MJ, Kohrt HE, et al. Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion. Blood 2009;114:3431-8.
17. Narazaki H, Zhu Y, Luo L, et al. CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cells. Blood 2010;115:1941-8.
18. McIlroy D, Barteau B, Cany J, et al. DNA/amphiphilic block copolymer nanospheres promote lowdose DNA vaccination. Mol Ther 2009;17:1473-81.
19. Cany J, Avril A, Pichard V, et al. A transgenic mouse with beta-Galactosidase as a fetal liver self-antigen for immunotherapy studies. J Hepatol 2007;47:396-403.
20. Cany J, Barteau B, Tran L, et al. AFP-specific immunotherapy impairs growth of autochthonous hepatocellular carcinoma in mice. J Hepatol 2011; 54:115-21.
21. Xia S, Sha H, Yang L, et al. Gr-11 CD11b1 myeloid-derived suppressor cells suppress inflammation and promote insulin sensitivity in obesity. J Biol Chem 2011;286:23591-9.
22. Melero I, Hervas-Stubbs S, Glennie M, et al. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007;7:95-106.
23. Giuntoli RL, II, Lu J, Kobayashi H, et al. Direct costimulation of tumor-reactive CTL by helper T cells potentiate their proliferation, survival, and effector function. Clin Cancer Res 2002;8:922-31.
24. Choi BK, Kim YH, Kim CH, et al. Peripheral 4-1BB signaling negatively regulates NK cell development through IFN-gamma. J Immunol 2010; 185:1404-11.
25. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003;3:23-35.
26. Ding T, Xu J, Wang F, et al. High tumorinfiltrating macrophage density predicts poor prognosis in patients with primary hepatocellular carcinoma after resection. Hum Pathol 2009;40:381-9.
27. Li YW, Qiu SJ, Fan J, et al. Tumor-infiltrating macrophages can predict favorable prognosis in hepatocellular carcinoma after resection. J Cancer Res Clin Oncol 2009;135:439-49.
28. Chew V, Tow C, Teo M, et al. Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients. J Hepatol 2010;52:370-9.
29. Fu J, Xu D, Liu Z, et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 2007;132:2328-39.
30. Hoechst B, Ormandy LA, Ballmaier M, et al. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(1)CD25(1)Foxp3(1) T cells. Gastroenterology 2008;135:234-43.
31. Newell P, Villanueva A, Friedman SL, et al. Experimental models of hepatocellular carcinoma. J Hepatol 2008;48:858-79.
32. Schneider C, Teufel A, Yevsa T, et al. Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer. Gut 2012;61:1733-43.
33. Morales-Kastresana A, Sanmamed MF, Rodriguez I, et al. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model. Clin Cancer Res 2013;19:6151-62.
34. Uno T, Takeda K, Kojima Y, et al. Eradication of established tumors in mice by a combination antibody-based therapy. Nat Med 2006;12:693-8.
35. Cheuk AT, Mufti GJ, Guinn BA. Role of 4-1BB:4-1BB ligand in cancer immunotherapy. Cancer Gene Ther 2004;11:215-26.
36. Kapanadze T, Gamrekelashvili J, Ma C, et al. Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma. J Hepatol 2013;59:1007-13.
37. Suzuki E, Kapoor V, Jassar AS, et al. Gemcitabine selectively eliminates splenic Gr-11/CD11b1 myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 2005;11:6713-21.
38. Ascierto PA, Simeone E, Sznol M, et al. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol 2010;37:508-16.
39. Dubrot J, Milheiro F, Alfaro C, et al. Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ. Cancer Immunol Immunother 2010;59:1223-33.
40. Niu L, Strahotin S, Hewes B, et al. Cytokinemediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137- treated mice. J Immunol 2007;178:4194-213.